Harrow, Inc. Director Departs; Officer Compensation & Filings
Ticker: HROW · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1360214
| Field | Detail |
|---|---|
| Company | Harrow, INC. (HROW) |
| Form Type | 8-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-departure, filings, officer-compensation
TL;DR
Harrow Inc. director Michael Enright out, filings submitted.
AI Summary
On January 17, 2025, Harrow, Inc. announced the departure of Director Michael J. Enright. The company also reported on compensatory arrangements for certain officers and filed financial statements and exhibits. Harrow, Inc. is a pharmaceutical preparations company based in Nashville, TN.
Why It Matters
The departure of a director can signal changes in company strategy or governance, while the filing of financial statements provides investors with updated financial performance information.
Risk Assessment
Risk Level: low — This filing primarily concerns a director's departure and routine financial filings, with no immediate indication of significant financial distress or major operational changes.
Key Players & Entities
- Michael J. Enright (person) — Departing Director
- Harrow, Inc. (company) — Filing Company
- 2834 (dollar_amount) — Standard Industrial Classification Code for Pharmaceutical Preparations
FAQ
Who is the departing director?
Director Michael J. Enright has departed from Harrow, Inc.
What is the primary business of Harrow, Inc.?
Harrow, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
When was the earliest event reported in this filing?
The earliest event reported is January 17, 2025.
What other items are covered in this 8-K filing?
The filing also covers the election of directors, appointment of certain officers, and compensatory arrangements of certain officers, in addition to financial statements and exhibits.
What is the company's fiscal year end?
Harrow, Inc.'s fiscal year ends on December 31.
Filing Stats: 491 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-01-21 07:00:35
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HROW The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 43KB
- 0001493152-25-002913.txt ( ) — 266KB
- hrow-20250117.xsd (EX-101.SCH) — 4KB
- hrow-20250117_def.xml (EX-101.DEF) — 30KB
- hrow-20250117_lab.xml (EX-101.LAB) — 36KB
- hrow-20250117_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 21 , 2025 HARROW, INC. By: /s/ Andrew R. Boll Andrew R. Boll Chief Financial Officer